Skip to main content

Advertisement

Table 3 In vivo phase I MST metabolites

From: Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry

  [M + H]+ PI RT (min) In vivo phase I metabolic reaction
MST 499 399 24.9  
M1 485 399 27.9 N-demethylation
M2 501 401 26.6 Carbonyl group reduction
M3 501 400.2, 367.3 24.4 N-demethylation and Hydroxylation of pyridine ring
M4 501 482.9, 399.3 26.5 N-demethylation and Hydroxylation of N-methyl piperazine
M5 529 511, 429 25.1 Benzyl oxidation to carboxylic acid
M6 529 486, 400 26.9 Pyridine ring hydroxylation and N-methyl piperazine oxidation
M7 529 511,482 399, 247 29.6 Oxidation and Hydroxylation of N-methyl piperazine
MO1 515 497.2, 415, 396.8 21.7 N-oxide formation
MO2 515 497.2, 396.9 22.2 Benzylic hydroxylation
MO3 515 497.0, 400.1 23.0 Pyridine ring hydroxylation
MO4 515 497, 399, 415, 217 23.1 Pyridine ring N-oxidation
MO5 515 497, 399, 415, 217 24.0 N-oxidation
MO6 515 428, 415, 400, 381.3, 98.1, 28.0 Piperazine ring N-oxidation
M8 531 488, 402, 123 26.7 Pyridine ring hydroxylation and piperazine ring hydroxylation
M9 531 415, 381, 123 27.3 Piperazine ring hydroxylation and benzyl hydroxylation
M10 531 501, 401 29.3 Oxidative cleavage of N-methyl piperazine ring to carboxylic acid
M11 547 511 30.7 N-oxide formation of pyridine and piperazine ring and Benzylic hydroxylation [27]
MA1 431 255 10.2 Oxidative deamination
MA2 447 271 13.2 Phenyl hydroxylation and oxidative deamination
MA3 447 285, 271, 164, 111 14.5 Benzyl hydroxylation and oxidative deamination